EXCLUSIVE: Stem Cell Focused BioRestorative Ventures Into $63B Aesthetics Market Via Supply Agreement With Evolutionary Biologics
Portfolio Pulse from Vandana Singh
BioRestorative Therapies Inc (NASDAQ:BRTX) has entered into a supply agreement with Evolutionary Biologics to manufacture tissue-based biologics for cosmetic and aesthetic applications. The initial order of 5,000 vials is expected to have a positive financial impact. The first product is an umbilical cord tissue extract enriched with factors that address signs of aging. Evolutionary Biologics, founded by former L'Oreal President Jim Morrison, supplies cosmetic-focused biologics to plastic surgeons, dermatologists, and medical spas in the U.S.
September 12, 2023 | 12:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
BioRestorative's new supply agreement with Evolutionary Biologics is expected to have a positive financial impact. The company's entry into the $62.8 billion global aesthetics market could drive efficiencies and expand its commercial business model.
The supply agreement with Evolutionary Biologics allows BioRestorative to enter the lucrative aesthetics market. The initial order of 5,000 vials is expected to have a positive financial impact, which could potentially boost the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100